Affymax Stock

Affymax AAQS

The The AAQS of Affymax (AFFY) as of Aug 17, 2026 is 7.

AAQS

7

Last updated:

Affymax has a current AAQS of 7.

A high AAQS can be seen as a positive indicator that the company is developing successfully.

Investors can assume that the company is on a good path to generate profits.

On the other hand, it is important to consider the AAQS of the stock Affymax in comparison to the profits generated and other companies in the same industry. A high AAQS is not an absolute guarantee for a positive future. Only in this way can one get a complete picture of the company's performance.

In order to better assess the company's development, it is important to consider the AAQS in comparison to other companies in the same industry. In general, investors should always consider the AAQS of a company in connection with other fundamentals such as profit, EBIT, cash flow, and others in order to make an informed investment decision.
Access this data via the Eulerpool API

Affymax Stock analysis

What does Affymax do? Affymax Inc is a leading biotechnology company specializing in the development of innovative therapeutics for patients with serious diseases. The company was founded in 2001 and is headquartered in Palo Alto, California. Affymax is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Affymax stock

The AAQS of Affymax is 7 in 2026.

On Eulerpool you can find the complete historical development of The AAQS Affymax since 2006 – with annual values, charts, and detailed analysis.

The AAQS is a key figure developed by AlleAktien.

The AAQS is a key figure developed by AlleAktien.

Access this data via the Eulerpool API

Quality — Affymax

All Key Metrics — Affymax